Breast Cancer Coverage From Every Angle
Advertisement
Advertisement

Shorter Course of Trastuzumab in Some HER2-Positive Early Breast Cancers

By: Joseph Cupolo
Posted: Tuesday, December 4, 2018

According to a subgroup analysis of the Short-HER trial, reported at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich (Abstract 191PD_PR), women with HER2-positive early breast cancer who have small tumors appear to have similar disease-free survival with a 9-week course of adjuvant trastuzumab as those who received 1 year of adjuvant therapy. In addition, the abbreviated course of treatment was associated with a lower risk of cardiac toxicity. Also presented at the Congress (Abstract LBA12_PR), the PERSEPHONE trial showed that a 6-month course of adjuvant trastuzumab was cost-effective compared with 12 months, with an average cost saving of nearly £10,000 (Euros 11,300) per patient and no apparent detriment to quality of life.

“Physicians can stop trastuzumab before 1 year in patients who develop a cardiac event during treatment without compromising efficacy and can consider shorter-duration trastuzumab treatment in patients at risk of cardiac toxicity and a low- or intermediate-risk of breast cancer relapse,” stated lead author of the Short-HER trial, Pierfranco Conte, MD, of the University of Padu, Italy, in an ESMO press release. However, he added, “Based on our data, 1-year trastuzumab remains the standard treatment for women with HER2-positive early breast cancer.”

In the randomized Short-HER trial, 1,254 patients with HER2-positive early breast cancer received either 9 weeks or 1 year of trastuzumab; all patients also received chemotherapy. Women at low- and intermediate-risk of relapse accounted for 89% of patients in the study.

After a median of 6 years of follow-up, patients with low- and intermediate-risk had similar 5-year disease-free survival with a 9-week course of trastuzumab (88%) as with 1 year (89%). However, their risk of cardiac events was nearly three times lower (4.5% vs. 12.8%).



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.